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Heart transplantation has been broadly performed in humans. However, occurrence of acute and chronic rejection has not yet
been resolved. Several inﬂammatory factors, such as cytokines and adhesion molecules, enhance the rejection. The graft arterial
disease (GAD), which is a type of chronic rejection, is characterized by intimal thickening comprised of proliferative smooth
muscle cells. Speciﬁc treatments that target the attenuation of acute rejection and GAD formation have not been well studied in
cardiac transplantation. Recent progress in the nucleic acid drugs, such as antisense oligodeoxynucleotides (ODNs) to regulate
the transcription of disease-related genes, has important roles in therapeutic applications. Transfection of cis-element double-
stranded DNA, named as “decoy,” has been also reported to be a useful nucleic acid drug. This decoy strategy has been not only
a useful method for the experimental studies of gene regulation but also a novel clinical strategy. In this paper, we reviewed the
experimental results of NF-κB, E2F, AP-1, and STAT-1 decoy and other ODNs using the experimental heart transplant models.
Copyright © 2009 Jun-ichi Suzuki et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Heart transplantation is a common surgical procedure in
humans. However, acute rejection and graft arterial diseases
(GADs), which are a phenomenon of chronic rejection,
have not yet been resolved [1, 2]. Several inﬂammatory
factors (e.g., cytokines and adhesion molecules) enhance
acute and chronic rejection. GAD is characterized by intimal
thickening comprised of proliferative smooth muscle cells
(SMCs) [3, 4]. Speciﬁc treatments that target the attenuation
of acute rejection and GAD were not studied in depth in
cardiactransplantation. Nucleic aciddrugs, suchasantisense
oligodeoxynucleotides (ODNs) to regulate the transcription
of disease-related genes, have an important role in therapeu-
tic applications. Transfectionof cis-elementdouble-stranded
DNA, named “decoy,” has also been reported to be a useful
nucleic acid drug [5, 6]. The nucleic acid drugs have been
not only a useful method for the experimental studies of
endogenous gene regulation, but also a novel clinical strategy
[7, 8]. In this paper, we reviewed the experimental results of
nucleic acid drugs using the experimental heart transplant
models.
2. AntisenseCyclin-Dependent
Kinase (cdk) 2 Kinase ODN
The enzyme cdk2 kinase plays an important role in cell
transition through the G1-S phase [9]. Recent progress
in the regulation of cell cycle progression has reinforced
the importance of the G1-S phase in the process of cell
proliferation [10]. However, the role of these cell cycle
regulatory genes in the pathophysiology of GAD was not
investigated. The antisense method, which uses a single-
strand DNA, is an innovative and attractive strategy to
block the transcription or translation of speciﬁc genes [5].
To test the eﬀect of antisense cdk2 kinase ODN on the
inhibition of GAD formation, we performed ODN transfer
into murine cardiac allografts. Donor hearts were infused
withtheantisensecdk2kinaseODN-HVJ-liposomecomplex2 Journal of Biomedicine and Biotechnology
solution from the descending aorta; the hearts were then
immediately transplanted into recipients. Treatment with
antisense cdk2 kinase ODN dramatically reduced arterial
intimal thickening with suppression of vascular cell adhesion
molecule (VCAM)-1. In the study, we clearly demonstrated
for the ﬁrst time that a single intraluminal administration
of antisense cdk2 kinase ODN prevents GAD formation
[11].
3. AntisenseProliferating-Cell
Nuclear Antigen (PCNA) ODN
Cell growth and proliferation are dependent on the coor-
dinated actions of multiple cell cycle regulatory genes.
A m o n gm a n yc e l lc y c l er e g u l a t o r yg e n e s ,P C N Ap l a y s
a critical role in the SMC proliferation [12]. Although
inhibition of arterial neointimal formation by antisense
PCNA ODN after balloon angioplasty in a rat carotid
injury model was reported [13], the eﬀect of antisense
PCNA ODN in preventing GAD was not tested. Therefore,
we performed single intraluminal delivery of the antisense
PCNA ODN into murine cardiac allografts. In the group
of no ODN or sense PCNA ODN transfection, the graft
coronary arteries were severely thickened. However, limited
neointimal formation was observed in antisense PCNA
ODN-transfected allografts. The cell cycle regulatory gene
PCNA plays an essential role in cell transition through
both the G1/S and G2/M phases [13]. Therefore, blocking
PCNA activation using antisense ODN regulates multiple
cell cycle phases, thus it prevents GAD formation eﬀectively
[14].
4. Antisense bcl-x ODN
Apoptosis is a prominent feature of atherosclerosis [15];
however, the role in GAD formation remains to be elu-
cidated. It is postulated that the regulation of apoptosis
involves the balance between proapoptotic mediators such
as bax, and antiapoptotic mediators such as bcl-x [16,
17]. However, the role of bcl-x in the pathophysiology
of GAD remains unclear. Recently, it was reported that
antisense bcl-x ODN is an eﬃcient therapeutic strategy for
prevention of neointimal formation after balloon injury of
rat carotid arteries [18]. We therefore hypothesized that
GAD could also be prevented by antisense bcl-x ODN.
Histologically, heavy neointimal thickening had formed in
the coronary arteries of sense bcl-x ODN transfected or
untreated allograft recipients; however in recipients treated
with antisense bcl-x ODN, arterial neointimal formation
was dramatically suppressed. Regarding apoptosis, lim-
ited TUNEL positive cells were observed in the arterial
thickened intima of allografts from nontreated or sense
bcl-x ODN-treated recipients. However, increased TUNEL
positive cells were seen in the mildly thickened intima of
the allografts treated with antisense bcl-x ODN. In the
study, we revealed that antisense bcl-x ODN inhibits arterial




ulatory genes, which are critical to the process of cell growth
and proliferation [20, 21]. Double-stranded DNA with high
aﬃnity for E2F acting as a decoy (E2F decoy) inhibits cell-
cycle regulatory gene expression and SMC proliferation in
rat carotid injury models [22]. However, the eﬀect of E2F
decoy in preventing GAD formation was not investigated. To
clarify the eﬀects, we used both murine and monkey cardiac
transplant models. Immunohistochemically, PCNA, c-myb,
cdk2, or cdc2 were expressed diﬀusely and strongly in the
thickened allograft arterial intima of untreated allografts;
whereas treatment with E2F decoy resulted in suppressed
expression in the endothelial cells of the mildly thickened
allograft intima. We revealed that E2F decoy transfer into
theallograftsspeciﬁcallyabolishedE2Factivityandinhibited
intimal hyperplasia (Figure 1). In addition, it was more
eﬀective than antisense ODN, because E2F decoy blocked
multiple cell cycle regulatory genes that bind to the same
cis element [23]. In the investigation of E2F decoy, we
used both rodent and nonhuman primate heart transplant
models. Although the rodent models could not exactly
represent human GAD, the animal models have been used as
appropriate investigation for long time. Because the primate
model demonstrated similar ﬁndings to both rodents and
humans, rodent allograft models are useful to analyze the
pathophysiology of human heart transplantation.
6. NF-κBDec o y
Antisense cdk2 kinase ODN and E2F decoy inhibit GAD
formation by suppressing cell cycle regulatory gene expres-
sion as demonstrated above. However, these nucleic acid
drugs could not attenuate acute rejection [11, 23]. Nuclear
f a c t o r - k a p p aB( N F - κB) plays a pivotal role in the coor-
dinated transcription of multiple inﬂammatory genes [24–
26]. However, the role of NF-κB in the pathophysiology of
acute rejection and GAD was not investigated. Since NF-
κB decoy inhibits the expression of several inﬂammatory
genes, we hypothesized that NF-κB decoy could attenuate
both acute rejection and GAD after transplantation. To
analyze the graft survival, donor hearts were infused with
NF-κB decoy-HVJ-AVE-liposome complex and transplanted
into recipients. In the major mismatch murine combination
group, nontreated or scrambled decoy transfected allografts
were acutely rejected, while NF-κB decoy transfection signif-
icantly prolonged allograft survival. Histologically, moderate
myocardial cell inﬁltration and heavy GAD formation was
observed in nontreated or scrambled decoy transfected
allografts, while NF-κB decoy markedly attenuated cell
inﬁltration and GAD formation. Immunohistochemically,
intercellular adhesion molecule (ICAM)-1 and vascular cell
adhesion molecule (VCAM)-1 were enhanced in nontreated
or scrambled ODN transfected allografts,while NF-κBd ec o y
transfection markedly suppressed the expression. In this
study, we demonstrated that NF-κB decoy inhibits intimal
hyperplasia eﬀectively; the prevention of neointimal forma-





Figure 1: Representative ﬁndings of allograft coronary arteries
are shown. (a) demonstrates the eﬀects of E2F decoy compared
to controls (b) on the intimal hyperplasia which deﬁnes cardiac
allograft vasculopathy. (Modiﬁed from reference [23].)
molecules which are directly aﬀected by NF-κBd e c o y .I ti s
also noteworthy that NF-κB decoy attenuates both chronic
rejection (GAD) and acute rejection in cardiac allografts.
Suppressed cell cycle regulatory genes, growth factors and
adhesion molecule expression were also observed in the
NF-κB decoy treated allografts; the phenomena may be con-
trolleddirectly and/or indirectly by NF-κB decoy throughout
the cytokine and chemokine network [27]. In the network,
ICAM-1, interferon-gamma and monocyte chemoattractant
protein-1 are the common factors to suppress these diseases
[2, 4]. Because NF-κB decoy regulates these factors, the
treatment has a signiﬁcant eﬀect for both acute and chronic
rejection.
7.AP-1andSTAT-1Decoy
Other transcription factors, signal transducer and activator
of transcription-1 (STAT-1) and activator protein-1 (AP-1),
are also important in the process of acute rejection and GAD
byregulatingvascularadhesionmoleculeexpression[28,29].
H¨ olschermann et al. and Stadlbauer et al. investigated the
eﬀects of STAT-1 decoy and AP-1 decoy to prevent acute
rejection and GAD using rat transplant models [30, 31].
They transplanted rat allografts after perfusion with STAT-
1 or AP-1 decoy. In acute rejection models, transfection
with AP-1 and STAT-1 decoy signiﬁcantly prolonged cardiac
allograft survival. Immunohistochemistry revealed a marked
reduction of myocardial inﬁltrating T-cells and adhesion
molecule expression on the endothelium in the decoy
transfected allografts [30]. In chronic rejection models, rat
cardiac allografts were perfused ex vivo with AP-1 decoy
ODN, STAT-1 decoy ODN, or buﬀer solution and trans-
planted into the abdomen of recipients with cyclosporine
immunosuppression. Treatment with both decoy attenuated
the incidence and severity of CAV. Histological analyses
revealed that AP-1 or STAT-1 decoy ODN treatment primar-
ily attenuated CD40 expression in the coronary endothelial
cells and medial smooth muscle cells [31]. They concluded
that treating donor hearts with decoy that is neutralizing
AP-1 or STAT-1 at the time of transplantation prevents both
acute and chronic rejection.
8. ODN Transfer Methods
Although a number of viral and nonviral vectors were
reported, no ideal vector has been established at this point.
Eachsystemhasuniquecharactersandpropertiesthatcanbe
used for speciﬁc conditions [32]. We have developed a gene
transfer vector by combining the hemagglutinating virus of
Japan (HVJ) and liposome. Using the system, we developed
an eﬀective method of gene transfer into the vessel wall and
myocardium [11,14,19].Itwasalsorevealedthatultrasound
can increase cell membrane permeability to macromolecules




In this paper, we demonstrated that transfection of nucleic
acid drugs attenuates both acute and chronic rejection. We
added an illustration that depicts the molecular pathways
targeted and how they ﬁt into the pathophysiology of the
diseasestargeted(Figure 2).Recently,clinicaltrialshavebeen
performed in cardiovascular diseases. For example, ex vivo
E2F decoy transfection in vascular grafts suppressed neoin-
timal hyperplasia after cardiac bypass surgery in humans
[36, 37]. We also tried the NF-κB decoy transfection in
the site of coronary arteries after stent implantation in
humans [38–40]. The results demonstrated that the strategy
is clinically promising. However, collateral and/or adverse
eﬀects by nuclear acid drugs have not yet been completely
resolved.Wereportedsomepossiblecollateraland/oradverse
eﬀects,suchaschestpain,skinrush,decreasingplatelets,and
liver dysfunction, in the NF-κB decoy treated patients [39].
Antisense bcl-2 oligonucleotide in patients with advanced
solid tumors showed liver dysfunction that was considered









Figure 2: An illustration which depicts the molecular pathways
targeted and how they ﬁt into the immunopathophysiology of the
diseases targeted is shown. (Modiﬁed from [6].)
antisenseoligonucleotideagainstinsulinreceptorsubstrate-1
to inhibit corneal neovascularization had some adverse
eﬀects such as painful eye and pressure sensation [42]. Thus,
further studies of nucleic acid drugs should be conducted
in other transplant models to explore the clinical utility for
prevention of acute rejection and GAD.
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